|Bid||0.00 x 0|
|Ask||0.00 x 0|
|Day's Range||0.00 - 0.00|
|52 Week Range|
|PE Ratio (TTM)||44.14|
|Dividend & Yield||0.95 (5.02%)|
|1y Target Est||N/A|
Pfizer, GlaxoSmithKline, and Novo Nordisk all offer up temptingly high yields. Here's why they're worth putting on your radar.
If you're concerned about a forthcoming market correction, GlaxoSmithKline, AT&T, and Procter & Gamble may be worth buying right now.
Sir, Joining in the discussion about GlaxoSmithKline's new plans, I find chief executive Emma Walmsley's strategic thinking on research and development questionable. I suggest it shows the terrible consequences ...